Axoltis Pharma
2025
Axoltis is a biotech company developing peptide-based therapeutics for neurological diseases. Focused on molecules capable of crossing the blood–brain barrier, including applications in ALS.
Website
More details...
Company Overview
CEO
Yann Godfrin
INVESTED IN
2025
SECTOR
Biotech
Why we invested
- Defensible IP around peptide therapeutics for CNS indications
- Clear and short path to exit for a biotech asset
- Advanced clinical stage reducing early scientific uncertainty
- Experienced team implying lower execution risk
- Attractive valuation creating a strong risk–reward profile at entry